Taiwan has discovered a new weapon for anti-epidemic! In addition to the Chinese Academy of Sciences and the National Health Institute, stepping up their pace and developing vaccines, the Chang Gung Hospital team also found a single antibody with potential from the confirmed cases, which can effectively inhibit Wuhan pneumonia virus capacity, up to 90% to 98% Applying for a patent, it is expected that the technology will be transferred in June, and the antibody drugs will be put on the market by the end of the year.
Put on isolation clothes, protective masks, medical examiners, enter the laboratory, and conduct Wuhan pneumonia and virus tests. This is the laboratory of Chang Gung Hospital, and now the hospital's research team has also developed potential monoclonal antibodies.
Huang Qionggui, deputy director of the Department of Laboratory Medicine of Linkou Changgeng Hospital: "The Wuhan strain and this virus strain we have sourced from Europe and the United States and Egypt have very good inhibitory effects.
Chang Gung University, Chang Gung Hospital, and the Chinese Academy of Sciences, the Institute of Preventive Medicine of the Ministry of Defense, and Oxford University formed a cooperative team. From the cases announced in early April, they found 25 human monoclonal antibodies that can be used to develop treatment and screening of Wuhan pneumonia tool.
Yang Zhengda, executive vice president of Linkou Changgeng Hospital: "When the virus infects the human body, it replicates in a certain cell, and when it comes out, it infects more cells and is blocked by our antibody. Going, it will stop the spread of this virus, and that will reduce the amount of virus, which has a therapeutic effect. "
Antibody drugs, antibody substances from humans, are not only safe and specific, but also will not affect the normal cell operation, which can reduce the occurrence of side effects and shorten the drug development time. The newly discovered monoclonal antibody is also applying for a patent. The technology transfer will start in June and it will be available at the end of the year.
In addition to the Chang Geng team, the Chinese Academy of Sciences and the National Institute of Health have also stepped up their efforts to develop high-end private vaccines in cooperation with the United States. Guoguang Biotech's vaccine has entered the animal experiment stage at National Taiwan University and hopes to conduct human trials by the end of the year. The national vaccine team mobilized to defend the health of the people of Taiwan.
